103 CF

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of:) Confirmation No. 8634))) Group Art Unit: 1652)
nilip A. COLE et al.	
Serial No. 09/811,870	
Filed: March 21, 2001) Examiner: D. Steadman)
For: Bisubstrate Inhibitors of Kinases) Atty. Dkt. No. 001107.00108

AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the non-final Office Action mailed April 29, 2004, applicants request reconsideration of the patentability of claims 1-15, 58, 60, 63, 66, 67, and 69-76. A petition for a two-month extension of time accompanies this paper, extending the time for responding to September 29, 2004. If it is determined that any additional fee is required, please charge our Deposit Account No. 19-0733.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.

Five attachments are included with this filing:

- 1. The structures of 2-amino-3-(4-amino-phenyl)-propionic acid, tyrosine, 2,3-diamino-propionic acid, serine, 2,3-diamino-butyric acid and threonine.
- 2. Extracts of Sigma Catalog showing examples of known nucleotides and nucleotide analogs
- 3. List of nineteen known peptide substrates of insulin receptor kinase.
- 4. List of eighty-two known peptide substrates of protein kinases.
- 5. Declaration Under Rule 132 of Dr. Philip A. Cole